ArticleBiotechnology for biofuels and bioproducts2025
High-level biosynthesis and purification of the antimicrobial peptide Kiadin based on non-chromatographic purification and acid cleavage methods.
Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combinatorial Effects of CPP-Modified Antimicrobial Peptides: Synergistic and Additive Interactions Against Pathogenic Bacteria.International journal of molecular sciences · 2025Article
- Nature's Arsenal: Uncovering Antibacterial Agents Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are renowned for their potent bacteriostatic activity and safety, rendering them invaluable in animal husbandry, food safety, and medicine. Despite their potential, the physiological toxicity of AMPs to host cells significantly hampers their biosynthetic production. This study presents a novel approach for the biosynthesis of the antimicrobial peptide Kiadin by engineering a DAMP4-DPS-Kiadin fusion protein to mitigate host cell toxicity and achieve high-level expression. Leveraging the unique properties of the DAMP4 protein, we developed a non-chromatographic purification method to isolate the DAMP4-DPS-Kiadin fusion protein with high purity. The instability of the D-P peptide bond under acidic conditions, combined with the thermal and saline stability of DAMP4, enabled efficient separation of Kiadin through acid cleavage and isoelectric precipitation, yielding Kiadin with 96% purity and a production yield of 29.3 mg/L. Our optimization of acid cleavage temperature, duration, and isoelectric precipitation conditions proved critical for maximizing the purification efficiency and expression levels of Kiadin. The biosynthesized Kiadin exhibited robust bacteriostatic activity against Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Bacillus cereus and Staphylococcus aureus. Notably, Kiadin demonstrated significant post-antibiotic effects by disrupting bacterial membrane integrity, inducing cytoplasmic leakage, and inhibiting biofilm formation in E. coli K88 and S. aureus Mu50, without cytotoxicity towards mouse macrophages. In vivo studies further confirmed Kiadin's exceptional therapeutic efficacy against abdominal infections caused by E. coli K88. The acid cleavage and non-chromatographic purification techniques developed in this study offer a cost-effective and efficient strategy for the high-purity production of AMPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.